Qlaris Bio appoints Fred Guerard as President and CEO

Lucy Batizovsky | March 18, 2026 | Appointment | |  Qlaris Bio 

Qlaris Bio, a clinical-stage biotechnology company, has appointed Fred Guerard as president and CEO. Guerard will also join the Board of Directors.

Previously, Guerard has served as CEO of Othea, president and CEO of Graybug Vision and worldwide franchise head of ophthalmology at Novartis.

Guerard said: “QLS-111 represents a differentiated and potentially transformative approach to lowering intraocular pressure by targeting the episcleral vein through its novel vasodilatory mechanism.

Advertisement

“I look forward to working with Qlaris’ talented team to advance our phase 3 programme and prepare the organisation for commercialisation.”

Qlaris develops first-in-class therapies for unmet needs in ophthalmology, including its lead candidate QLS-111 which is designed to treat glaucoma.

Guerard has more than two decades of global leadership experience in ophthalmology.

Related Content

No items found
The Gateway to Local Adoption Series

Latest content